A Game-Changer by Roche and Chugai | NXT007: For Hemophilia A, Without Inhibitors
The National Bleeding Disorders Foundation (NBDF) posted in appreciation of Roche and Chugai on X:
”Roche and Chugai recently presented new data on NXT007, an investigational bispecific antibody therapy for people with hemophilia A without inhibitors. Phase III studies are planned to begin in 2026.”
To learn more about this advancement, follow the link.
The promising findings—because we can never have too many early-stage breakthroughs—were shared during recent scientific presentations, hinting at NXT007’s potential to once again reshape prophylactic treatment for this ever-hopeful patient population.
Roche and Chugai have recently unveiled new data on NXT007, an investigational bispecific antibody therapy designed for individuals with hemophilia A without inhibitors.
NXT007, engineered to mimic the function of activated factor VIII, builds upon the success of emicizumab and is designed to offer improved pharmacokinetics and efficacy.
Looking ahead, Phase III clinical trials of NXT007 are expected to begin in 2026, marking a significant step forward in evaluating the therapy’s long-term potential and its role in reducing bleeding episodes and improving quality of life for patients!
Find more on drug advancements in the field of Hemophilia management in Hemostasis Today.
-
Jul 5, 2025, 17:24Bleeding Disorders in 2035: Michael Makris is Future-Focused at HABIT Summit 2025
-
Jul 5, 2025, 16:32EHC Unveils New ERIN Identity: Supporting Individuals with Extremely Rare Bleeding Disorders
-
Jul 5, 2025, 16:30Calling Physiotherapists: Contribute to Shaping Care for Women with Bleeding Disorders by Sharing Insights on Physical Health and Physiotherapy
-
Jul 5, 2025, 16:26Access ISTH 2025 Congress On-Demand: 30 Days of Virtual Learning Available Now
-
Jul 5, 2025, 16:17Thrombosis Canada Wants Your Voice: Did You Know 1 in 5 Cancer Patients Will Experience a Blood Clot (VTE)?
-
Jul 5, 2025, 17:38Late-Window Stroke: Hyperglycemia Doesn’t Alter EVT Benefit
-
Jul 5, 2025, 17:33Discharged, But Not Safe: Uncovering Hidden Risks of Anticoagulation for Post-Hospital Bleeding
-
Jul 2, 2025, 16:51Research Tuesday from SVIN: IV Thrombolysis in Cervical Artery Dissection—A Safer Path Home?
-
Jul 2, 2025, 05:34Redefining Life with Catastrophic Antiphospholipid Syndrome: Mark Hall’s Journey at U-M Health
-
Jul 1, 2025, 07:18Bleeding Risk Scores in Anticoagulated PE Patients - Thrombosis and Hemostasis
-
Mar 6, 2025, 17:15Olympus Announces Launch of Single-Use Hemostasis Clip
-
Jun 30, 2025, 15:31Don’t Miss the Advanced Haemostasis and Thrombosis Course Led by Expert Tutors - Blood Academy
-
Jun 26, 2025, 14:33ISTH Pulse Podcast Episode with Vasculearn Network
-
Jun 22, 2025, 11:27The ISTH Congress Daily News Team Interviews Rob Montgomery
-
Jun 22, 2025, 07:54Flora Peyvandi: Congratulations to Robert Montgomery! Thanks For All Your Work For Our Society
-
Jun 21, 2025, 20:12Flora Peyvandi: Thanks, Claire, for All You Have Done for the Women and Early Career Members of the ISTH